The FDA has released a warning about the potential for an increase in disability in patients with multiple sclerosis who stop taking this immunosuppressant.
The FDA has approved a generic option for the treatment of patients with relapsing forms of multiple sclerosis. For details, including dosage and common adverse effects, read more.